Geron Corporation Reports $49M Revenue in Q2 2025, Significant Growth from Previous Year

Geron Corporation reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2025. The company generated total revenues of approximately $49.0 million for the second quarter, a substantial increase from $0.8 million in the same period last year. For the first half of 2025, total revenues reached $88.6 million, compared to $1.2 million in the first half of 2024. The increase in revenue is primarily attributed to the sales of RYTELO, which the company began commercializing in June 2024 following FDA approval. The net product revenue for the second quarter was $49.0 million, while the first half saw net product revenue of $88.4 million.

In terms of expenses, Geron reported total operating expenses of $61.5 million for the second quarter, down from $70.2 million in the same period last year, reflecting a 12% decrease. For the first half of 2025, total operating expenses were $117.8 million, a 7% decrease from $126.7 million in the first half of 2024. The reduction in expenses was driven by lower research and development costs, which fell by 29% in the second quarter and 39% in the first half, as the company capitalized on manufacturing costs following the FDA approval of RYTELO. Despite these reductions, Geron reported a net loss of $16.4 million for the second quarter, significantly improved from a loss of $67.4 million in the same period last year.

Strategically, Geron has made notable advancements, including the recent marketing authorization of RYTELO by the European Commission for use in specific patient populations. The company is preparing for commercialization in select EU markets in 2026, planning to collaborate with third parties for marketing and distribution. Additionally, Geron is advancing its clinical trials for imetelstat, with the Phase 3 IMpactMF trial nearing completion of enrollment, expected by the end of 2025.

Operationally, Geron reported an increase in inventory, which rose to $69.1 million as of June 30, 2025, compared to $38.7 million at the end of 2024. This increase reflects the company's preparations for ongoing and future sales of RYTELO. The company also reported a cash position of approximately $432.6 million, down from $502.9 million at the end of 2024, primarily due to cash used in operations. Geron continues to focus on expanding its market presence and enhancing its commercialization strategy for RYTELO, while also managing its operational costs effectively.

Looking ahead, Geron anticipates that its operating expenses will increase as it invests in the commercialization of RYTELO and prepares for its launch in the EU. The company expects to continue generating revenue from RYTELO sales, but acknowledges the inherent uncertainties in drug commercialization and the potential need for additional funding to support its operations and growth initiatives.